Biotechnology
Commented by Stefan Feulner on November 11th, 2025 | 07:00 CET
Vistra, NetraMark, Snap – AI stocks with potential
The bull market of recent months has given way to disillusionment, as AI stocks were sold off last week despite strong quarterly results. Is hedge fund manager Michael Burry, famous from "The Big Short," right again? According to the latest 13F filing from Scion Asset Management, Burry holds put options on Nvidia and Palantir with a total value of around USD 1.1 billion and is betting on sharply falling prices. He points to the exceptionally high valuations of these companies as the reason for his pessimism. However, not all stocks in the field of artificial intelligence are overpriced. Some promising names with significant upside potential can still be found among the second-tier players.
Read
Commented by Nico Popp on November 10th, 2025 | 07:10 CET
Patient well-being as the key to returns: Oramed Pharmaceuticals, Roche, BioNxt
Higher, faster, further – constant progress is not only important in sports. The economy and science are also all about continuous innovation and improvement. Biotechnology combines both areas. We show how new, patient-centered approaches can capture market share and also create added value for investors. To this end, we take a look at the Swiss pharmaceutical company Roche, show how the Israeli biotech company Oramed has learned from setbacks, and how BioNxt Solutions is securing promising patents with innovative dosage forms.
Read
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by André Will-Laudien on November 4th, 2025 | 07:30 CET
Amazing! Rollercoaster ride with Beyond Meat, recovery at Novo Nordisk and Eli Lilly, big returns with PanGenomic Health
Volatility in the growth stock sector has caused quite a few swings in recent weeks. While Novo Nordisk and Eli Lilly are still struggling with margin declines from semaglutide injections, shares of the plant-based meat provider Beyond Meat have been bouncing around like a ball in orbit. After a rapid tenfold increase in October, November appears to be all about the reverse gear, with the stock currently down 80% from its peak. Those with strong nerves and a quick hand on the mouse are in luck. Things are calmer and steadier with PanGenomic Health. Here, the high levels since summer must first be digested before the next upward cycle can begin. We highlight a few opportunities.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:25 CET
A new era in medicine is dawning: How Novo Nordisk, NetraMark Holdings, and Bayer are benefiting from AI and personalization
The healthcare industry is on the cusp of a new era, driven by AI-powered personalized therapies that are not only prolonging lives but also reshaping markets worth billions. Those who identify the pioneers of this transformation early on could benefit from extraordinary growth opportunities. Three companies, Novo Nordisk, NetraMark Holdings, and Bayer, are positioning themselves at the heart of this profitable field with groundbreaking technologies and therapies.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:15 CET
BioNxt Solutions: The underrated biotech gem you need to know - Potential partner for Merck and Novo Nordisk
Investing in biotech often feels like a rollercoaster ride. The sector regularly delivers groundbreaking success stories, yet just as often, promising studies come to nothing. For investors, this usually means a nerve-wracking journey with long dry spells and a true all-or-nothing gamble. But what if there was a way to avoid the typical risks without sacrificing the enormous upside potential? The Canadian company BioNxt Solutions is pursuing precisely this approach and could very well change the rules of the game in the biotech industry.
Read
Commented by Nico Popp on October 29th, 2025 | 07:30 CET
AI fantasy at biotech innovators: BioNxt, Roche, Merck & Co.
Biotechnology provides us with the medicines of tomorrow. But even with established active ingredients, innovation is possible. A prime example of this is the Canadian-German company BioNxt Solutions. This article outlines the strategy BioNxt is pursuing, which companies the emerging biotech startup could connect with, what new opportunities AI offers for its business model, and what this could mean for BioNxt shareholders.
Read
Commented by Fabian Lorenz on October 28th, 2025 | 07:15 CET
Better than BioNTech, Evotec & Co.? BioNxt Solutions faces key milestones and is considering an AI takeover – Stock in an upward trend
An exciting alternative to Evotec, BioNTech, and similar companies is BioNxt Solutions. The Canadian-German company's business model is a refreshing departure from traditional biotech companies with their huge research costs. BioNxt reformulates already approved active ingredients. For instance, Ozempic is set to be taken orally instead of by injection in the future. The sublingual cladribine formulation for multiple sclerosis is already well advanced, with its preclinical phase nearing completion. At the same time, CEO Hugh Rogers is considering an acquisition in the field of artificial intelligence to further accelerate development processes. The aforementioned development in the billion-dollar obesity market is also exciting. If a breakthrough succeeds, the Company could soon become a takeover candidate for Big Pharma.
Read